Dose-dependent effects of lesogaberan on reflux measures in patients with refractory gastroesophageal reflux disease: a randomized, placebo-controlled study

BACKGROUND: The γ-aminobutyric acid type B-receptor agonist lesogaberan (AZD3355) has been developed for use in patients with gastroesophageal reflux disease (GERD) symptoms despite proton pump inhibitor (PPI) therapy (partial responders). This study aimed to explore the dose–response effect of leso...

Descripción completa

Detalles Bibliográficos
Autores principales: Miner, Philip B, Silberg, Debra G, Ruth, Magnus, Miller, Frank, Pandolfino, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4289246/
https://www.ncbi.nlm.nih.gov/pubmed/25407279
http://dx.doi.org/10.1186/1471-230X-14-188

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4289246/
https://www.ncbi.nlm.nih.gov/pubmed/25407279
http://dx.doi.org/10.1186/1471-230X-14-188

Ejemplares similares